Open Access Critical Evidence Review

Insights into circulating CEACAM1 in insulin clearance and disease progression: evidence from the Portuguese PREVADIAB2 study - Evidence review

The PREVADIAB2 study associates lower circulating levels of CEACAM1 and reduced insulin elimination with worse metabolic profiles, especially before overt diabetes. Other research confirms that reduced clearance contributes to hyperinsulinemia in obesity. However, the human causal link and the diagnostic use of CEACAM1 require independent prospective validation in external cohorts.

Cite this article
Mondini, M. (2026). Insights into circulating CEACAM1 in insulin clearance and disease progression: evidence from the Portuguese PREVADIAB2 study - Evidence review. Life Science Hub Journal. DOI: 10.5281/zenodo.24306405. https://lifesciencehub.info/en/insights-into-circulating-ceacam1-in-insulin-clearance-and-disease-progression-evidence-from-the
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24306405

Article history
Dates
  • Published 16/11/2026
  • Updated 17/11/2026
Revisions
  1. v1.0 — 16/11/2026 Initial publication of the article.
  2. v1.1 — 17/11/2026 Editorial update of content, sources or references.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Scientific composition on the liver, CEACAM1, and insulin clearance, with visual signs of steatosis and altered metabolism.
Scientific representation of insulin clearance: the liver and metabolic profile worsen together as obesity and steatosis increase, with lower CEACAM1 in the blood.

ABSTRACT

The analyzed study evaluated whether the blood concentration of CEACAM1, a protein involved in the hepatic clearance of insulin, reflects alterations in insulin metabolism in 1,019 adults from the Portuguese PREVADIAB2 cohort. As subjects progressed from normoglycemia to prediabetes and type 2 diabetes, body mass index, insulin resistance, insulinemia, and the frequency of hepatic steatosis increased, while circulating levels of CEACAM1 were found to be lower compared to normoglycemia.

In the narrative of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the publication contributes to the passage stating that more compromised metabolic profiles also exhibit a lower capacity to clear insulin, and that this relationship is more recognizable in less compromised subjects. Independent studies in humans confirm that obesity and fat accumulation in the liver are associated with a reduction in insulin clearance; animal models also support a possible causal role for the loss of hepatic CEACAM1. However, the cross-sectional design does not establish the temporal sequence in humans, and circulating CEACAM1 is not yet a clinically validated biomarker.

Analyzed study

Insights into circulating CEACAM1 in insulin clearance and disease progression: Evidence from the Portuguese PREVADIAB2 study

Patarrão RS, Meneses MJ, Ghadieh HE, Herrera L, Duarte S, Ribeiro RT, Raposo JF, Schmitt V, Singer BB, Gastaldelli A, Penha-Gonçalves C, Najjar SM, Macedo MP

European journal of clinical investigation, 2024

DOI: 10.1111/eci.14344

PMID: 39674875

PMCID: PMC11646293

The research question was whether blood levels of CEACAM1, a glycoprotein primarily found in liver cells, could reflect the body's ability to clear insulin. This elimination, known as insulin clearance, prevents the hormone from remaining in circulation longer than necessary.

The hypothesis was biologically plausible: in the liver, CEACAM1 participates in the entry of the insulin-receptor complex into the cell, a necessary step for the degradation of the hormone. The study is relevant to section 3.4 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi because it evaluates, in a human population, whether a profile characterized by greater adiposity, hepatic steatosis, and insulin resistance is accompanied by lower insulin clearance and lower levels of circulating CEACAM1.

The publication documents associations observed at a single point in time. It can therefore show that certain metabolic characteristics tend to occur together, but it cannot prove that the decrease of CEACAM1 in the blood causes the reduction in insulin clearance, nor that the latter necessarily precedes diabetes.

Materials and methods of the original study

The authors analyzed a cross-sectional cohort—a snapshot of health status collected over a specific period—consisting of 1,019 participants from the Portuguese PREVADIAB2 program. The median age was 62 years, and 60% of the participants were women. In 2014, all participants underwent an oral glucose tolerance test with 75 g of glucose, with blood samples taken at fasting, 30 minutes, and 120 minutes.

Based on the 2019 World Health Organization criteria, 735 individuals had normoglycemia, 226 had prediabetes, and 58 had newly diagnosed type 2 diabetes. Subjects already diagnosed and pharmacologically treated for diabetes and those without available biological samples were excluded. CEACAM1 was measured in the serum using ELISA, an immunological technique that quantifies a protein using specific antibodies.

The authors estimated fasting and early post-glucose insulin secretion, fasting insulin clearance, and insulin resistance using HOMA-IR, an index calculated from fasting glycemia and insulin. They also used the Fatty Liver Index, an indirect index of probable hepatic steatosis. Differences between groups were evaluated using non-parametric tests; data are reported as median and interquartile range. A hierarchical analysis classified 945 participants—those with complete data for all included variables—into four metabolic profiles.

Results

Worsening glucose tolerance was accompanied by a less favorable metabolic profile. The median BMI increased from 26 kg/m² in normoglycemia to 28 in prediabetes and 29 in type 2 diabetes. The proportion of individuals with a Fatty Liver Index of at least 60, indicative of a high probability of steatosis, increased from 26% to 46% and 60%. HOMA-IR also increased from 1.2 to 1.9 and 2.5: a higher value indicates greater insulin resistance.

Fasting insulin increased from 5.8 μIU/mL in normoglycemic individuals to 8.5 in prediabetes and 10.0 in diabetes. In the same comparison, estimated basal insulin secretion increased from 143 to 180 and 215 pmol/min. Conversely, the early insulin response to glucose decreased: the insulinogenic index went from 0.73 in normoglycemia to 0.45 in prediabetes and 0.26 in diabetes. Simply put, as metabolic damage increased, the pancreas produced more fasting insulin but responded less readily to glucose.

The result most relevant to the book concerns insulin clearance and CEACAM1. The median circulating CEACAM1 was 29.8 ng/mL in normoglycemia, 26.6 ng/mL in prediabetes, and 27.3 ng/mL in diabetes; the differences compared to normoglycemia were statistically significant. In prediabetes, fasting insulin clearance was lower than in normoglycemia, with median values of 3.8 versus 4.0 L/min; clearance during the glucose tolerance test was also lower, 0.16 versus 0.17. In the newly diagnosed diabetes group, however, clearance was not further reduced.

In the analysis by metabolic profiles, the group with the worst overall picture, representing 25% of the classified participants, had the highest BMI, a greater prevalence of steatosis, higher HOMA-IR, and the lowest clearance. Compared to the most metabolically favorable group, it had a fasting clearance of 3.1 versus 4.9 L/min and CEACAM1 levels of 26.3 versus 27.5 ng/mL. Positive correlations between CEACAM1 and clearance were more recognizable in the less compromised clusters, but the authors themselves note that their intensity was low and varied between groups.

Interpretation

The primary significance is that hyperinsulinemia, meaning an elevated amount of insulin in the blood, does not depend solely on how much insulin is produced by the pancreas. It also depends on how quickly the liver and other organs remove it from circulation. In the Portuguese cohort, profiles associated with greater adiposity, hepatic steatosis, and insulin resistance showed, on average, lower insulin clearance.

The segment specifically documented by the publication is therefore: lower efficiency in insulin elimination associated with a more compromised metabolic profile, with a relationship between circulating CEACAM1 and clearance that is more recognizable in people with normoglycemia or less metabolic impairment. This is why the study appears in the section dedicated to insulin clearance and hyperinsulinemia.

The biological interpretation proposed by the authors is that lower levels of CEACAM1 in the blood may reflect lower availability of the same protein in the liver. However, blood levels do not indicate with certainty the quantity or activity of CEACAM1 in liver cells. Furthermore, other processes can modify clearance, including insulin-degrading enzymes and renal elimination. For this reason, circulating CEACAM1 should be considered a promising association, not diagnostic or causal evidence.

Independent supporting evidence

Particularly relevant human confirmation comes from two independent cohorts studied by Fu and colleagues. The first included 460 participants evaluated with an oral glucose tolerance test; in the second, 81 people underwent intravenous tests and a hyperinsulinemic-euglycemic clamp, a procedure that more directly measures insulin sensitivity and hormone dynamics. All obese participants showed lower insulin clearance compared to lean controls. Among obese individuals without diabetes, clearance decreased progressively as insulin resistance worsened, while secretion did not increase in the early stages. This directly confirms the passage in the book stating that reduced insulin elimination can contribute early on to the hyperinsulinemia associated with obesity [1]. The limitation is that this work is also primarily observational and does not demonstrate which biological alteration initiates the process.

A second human study examined 190 people, including 32 without hepatic steatosis, 36 with simple steatosis, and 122 with biopsy-confirmed steatohepatitis. Hepatic insulin clearance was approximately 30% lower in both simple steatosis and steatohepatitis compared to controls without steatosis. There was no significant difference in insulin secretion between simple steatosis and steatohepatitis. This reinforces the link between increased steatosis and reduced hepatic insulin elimination presented in the book's narrative [2]. However, the result does not prove that liver fat is the sole cause of reduced clearance, because adiposity and insulin resistance can occur simultaneously.

The relationship between hepatic CEACAM1, clearance, and metabolic consequences is experimentally supported by a mouse model with liver-specific Ceacam1 deletion. The mice first developed reduced insulin clearance and hyperinsulinemia as early as two months, followed by hepatic insulin resistance and steatohepatitis around seven months [3]. This sequence causally supports the chain of reduced hepatic CEACAM1 function → reduced clearance → hyperinsulinemia → metabolic alterations in the animal model. This is an important mechanistic confirmation, but it does not prove that CEACAM1 measured in human blood has the same function or the same prognostic value.

Conflicting evidence

The relationship does not appear uniform across every metabolic condition. In the same original study, insulin clearance was reduced in prediabetes but not in the group with newly diagnosed type 2 diabetes; furthermore, some clusters showed reduced clearance without particularly low levels of CEACAM1. This indicates that the link between the circulating protein and clearance depends on the clinical context and cannot be interpreted as a constant one-to-one ratio.

A study of 70 women with gestational diabetes and 70 pregnant women with normal glucose tolerance did not find a statistically significant difference in mean CEACAM1 levels between the groups. Within the gestational diabetes group, however, higher CEACAM1 was associated with greater insulin sensitivity and lower insulin levels after a meal [4]. This evidence does not contradict the biological plausibility of the protein, but it scales back the idea that its circulating value reliably identifies every form of dysglycemia or insulin resistance.

No directly conflicting evidence sufficiently relevant to the specific relationship between circulating CEACAM1 and insulin clearance in non-pregnant adults has been identified; this does not prove the absence of contrary findings.

Summary table of evidence

The table distinguishes the observational data from the analyzed publication from independent confirmations and the evidence that defines its generalizability limits.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Cross-sectional observational 1,019 adults from the PREVADIAB2 cohort Prediabetes and worse metabolic profiles associated with lower insulin clearance and lower circulating CEACAM1; relationship more recognizable in less compromised subjects direct confirmation moderate
[1] Observational with two cohorts and complementary physiological measurements 460 participants in the first cohort and 81 in the second In obesity, insulin clearance was reduced; in the early stages of insulin resistance, it decreased before the increase in secretion direct confirmation moderate
[2] Clinical observational 190 adults with no steatosis, simple steatosis, or steatohepatitis Simple steatosis and steatohepatitis associated with approximately a 30% reduction in hepatic clearance compared to controls direct confirmation moderate
[3] Experimental animal Mice with hepatic Ceacam1 deletion and controls Lower clearance and hyperinsulinemia preceded hepatic insulin resistance and steatohepatitis biologically consistent evidence moderate
[4] Clinical observational 70 women with gestational diabetes and 70 pregnant women with normal tolerance No significant difference in CEACAM1 between groups; in gestational diabetes, higher CEACAM1 associated with greater insulin sensitivity discordant evidence low

Confirmation of the evidence

Claim in the book

In section 3.4 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the relevant statement is that, in the PREVADIAB2 cohort, the transition from normoglycemia to prediabetes and diabetes is associated with increased adiposity, insulin resistance, insulinemia, and steatosis; subjects with the worst metabolic profile also show a lower capacity to clear insulin. The correlation is described as being more evident in normoglycemic and less compromised subjects.

Increased adiposity and hepatic steatosis → reduced insulin clearance → greater circulating insulin exposure → hyperinsulinemia and insulin resistance

The publication subject to the Evidence Review was used in the book to support the following passage: in participants with more compromised metabolic profiles, characterized by higher BMI, hepatic steatosis, and insulin resistance, the capacity to clear insulin is lower; the association between circulating CEACAM1 and clearance is more recognizable in less compromised individuals.

The correspondence with the text "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi is direct on an observational level: the original study shows, in the same cohort, the association between a worsening of the lipid profile, lower insulin clearance, and differences in circulating CEACAM1 levels. However, it does not demonstrate that every increase in insulin derives primarily from reduced clearance, nor that circulating CEACAM1 directly measures the active protein in the liver.

Independent evidence strengthens the central chain. Two cohorts of people with obesity showed a reduction in insulin clearance, which was progressively greater with insulin resistance and present before the increase in secretion in the early stages [1]. In people with simple steatosis or steatohepatitis, hepatic clearance was approximately 30% lower compared to those without steatosis, with no significant difference in secretion between the two forms of liver disease [2]. Finally, in mice, the loss of CEACAM1 in the liver temporally preceded hyperinsulinemia, hepatic insulin resistance, and steatohepatitis [3].

The least consolidated part concerns the use of CEACAM1 in the blood as a clinical indicator. In pregnancies with gestational diabetes, mean levels did not differ significantly from controls, although they were internally associated with greater insulin sensitivity [4]. The literature therefore strongly supports the relevance of clearance in the metabolic profile, while only moderately supporting the interpretation of circulating CEACAM1 as a general biomarker.

Overall level of confirmation

MODERATE CONFIRMATION

The finding regarding lower insulin clearance in worse metabolic profiles is confirmed by independent human studies and a causal animal model. The specific relationship between circulating CEACAM1 and clearance, however, stems primarily from cross-sectional data and shows variability across clinical conditions; it therefore requires prospective validation in diverse populations.

Conclusions

The study analyzed pertinently supports the narrative that hyperinsulinemia does not depend exclusively on pancreatic secretion: reduced insulin clearance contributes to the metabolic profile associated with obesity, steatosis, and insulin resistance. This part of the narrative is moderately supported by independent evidence in humans.

The possible role of CEACAM1 is well-supported at a mechanistic level in animal models. In humans, however, circulating levels of the protein currently represent a promising observational signal, but not a validated diagnostic test. Longitudinal studies are needed to verify whether CEACAM1 truly anticipates the reduction in clearance or the progression toward diabetes and steatosis.

Overall assessment

The narrative regarding reduced insulin clearance in more compromised metabolic profiles is fairly well supported by independent human studies. The causal role of CEACAM1 is confirmed primarily at the mechanistic animal level. The use of circulating CEACAM1 as a biomarker in humans remains moderately supported and requires prospective validation.

References

[1] Impaired Insulin Clearance as the Initial Regulator of Obesity-Associated Hyperinsulinemia: Novel Insight Into the Underlying Mechanism Based on Serum Bile Acid Profiles

Fu Z, Wu Q, Guo W, Gu J, Zheng X, Gong Y, et al., 2022

Diabetes Care

[2] Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis

Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, et al., 2014

Hepatology

[3] Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis

Ghadieh HE, Russo L, Muturi HT, Ghanem SS, Manaserh IH, Noh HL, et al., 2019

Metabolism

[4] Association of circulating CEACAM1 levels and insulin sensitivity in gestational diabetes mellitus

Wu Y, Yang Z, Zhu L, Su Q, Qin L, 2020

BMC Endocrine Disorders

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.